CD274 and non-small cell lung carcinoma: Additionally, we showed that CDK7 inhibition reactivated immunity by suppressing p38α/MYC/PD-L1 and sensitized cancer cells to anti-PD1 therapy in vivo, which indicated CDK7 as an attractive target for epigenetic therapy of NSCLC.